Hamid Tabatabaie’s Post

The #DiabeticFootUlcerTherapeutic market continues to witness significant investments aimed at enhancing treatment outcomes and patient care. In 2024, several key players have made noteworthy strides: 3M has recently increased its investment in advanced wound care technologies, aiming to boost its market share with innovative solutions that enhance healing rates. 3M Smith & Nephew announced a $50 million investment in research and development for their advanced dressings and biologics, targeting improved outcomes for DFU patients. Smith+Nephew Mölnlycke Health Care has launched a new initiative focusing on sustainable wound care products, with an allocation of $30 million aimed at expanding its portfolio for diabetic foot ulcers. Mölnlycke Health Care ConvaTec reported a significant growth in its DFU product line, with a $40 million investment in clinical studies to validate the effectiveness of their latest advanced dressings. Convatec Coloplast is enhancing its R&D with a $25 million fund aimed at developing innovative technologies specifically designed for DFU management. Coloplast Integra LifeSciences announced a $20 million investment for expanding its regenerative medicine offerings tailored for diabetic foot ulcers. Integra LifeSciences Essity (BSN Medical) is focusing on its product line for chronic wound care with a $35 million investment, emphasizing enhanced patient care. @Essity Medline has launched a new educational program with a $15 million budget to train healthcare professionals on the latest DFU management techniques. Medline Industries, LP B. Braun continues to innovate with a $22 million investment aimed at expanding its advanced wound care offerings, specifically targeting diabetic patients. B. Braun Group Organogenesis is advancing its research initiatives with a $28 million investment in new biological therapies for diabetic foot ulcer treatment. Organogenesis Read Report @ https://lnkd.in/gCiF5zxr #Healthcare #DiabetesCare #WoundHealing #ChronicWounds #DFU #AdvancedWoundCare #HealthInnovation #RegenerativeMedicine #PatientCare #MedicalDevices #HealthcareInvestments #ClinicalResearch #SustainableHealthcare #HealthcareTechnology #Biologics #Nursing #Podiatry #WoundCare #MedicalResearch #HealthEconomics #DiabeticFootUlcer #DFUTherapeutics #WoundCareResearch #ChronicWoundManagement #DiabetesComplications #WoundCareInnovation #DFUManagement #DiabeticWounds #WoundHealingTechnologies #HealthInvestment #DiabetesAwareness #HealthcareTrends #WoundCareProducts #InnovativeWoundCare #FootUlcerTreatment #DFUTreatment #DiabetesResearch #AdvancedDressings #HealthTech #RegenerativeWoundCare #MedicalInnovation

𝐖𝐡𝐚𝐭 𝐢𝐬 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐚𝐧𝐝 𝐢𝐬 𝐢𝐭 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞? 𝐆𝐞𝐭 𝐀 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 (220+ 𝐏𝐚𝐠𝐞𝐬 𝐏𝐃𝐅 𝐰𝐢𝐭𝐡 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐂𝐡𝐚𝐫𝐭𝐬, 𝐓𝐚𝐛𝐥𝐞𝐬, 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬) @ https://lnkd.in/dEKGsDXf   As science evolves, healthcare is rapidly moving towards precision medicine, which offers a greater understanding of diseases using genetic insights and other medical advances in technology. Precision medicine, also known as personalised medicine, is a novel approach for disease treatment and prevention that considers the individual variability in genetics, environment, and lifestyle for each patient. This approach allows healthcare providers to make a more accurate diagnosis and create specialist treatment plans.   Historically, the practice of drug development has largely been reactive. Patients must usually wait for the onset of symptoms before they are treated or cured. As we do not yet fully understand the genetic or environmental factors that cause some major diseases and leading causes of death such as Alzheimer’s and cancer, efforts to treat these diseases are often inaccurate and unsuccessful. This movement in medicine, away from a one-size-fits-all approach, is crucial as it provides not just the opportunity to reduce the adverse side effects but also has the potential to reduce the cost of treatments by eradicating ineffective treatment plans.   Drugs and treatments created by pharmaceutical companies are often used to treat broad populations and consequently, they work for some patients but not others. It is estimated that any given prescription drug that makes it to market only works for half of those who take it. By considering each patient as an individual, precision medicine has the potential to overcome the limitations of traditional medicine by shifting the emphasis from reaction towards prevention.   𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐛𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐨𝐟 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞? By identifying the risk of a patient developing a disease they can be provided with an effective prevention plan, reducing unnecessary suffering for patients. This is also beneficial to society as it lessens the financial burden of illness and ineffective treatments on healthcare systems. If patients do contract a disease, then precision medicine has the potential to prevent unfavourable side effects. With medical precision, it is also possible to identify the most beneficial treatment plan before trying other methods, speeding up the recovery process and potentially extending life expectancy. Precision medicine also reduces the time, cost and failure rate of pharmaceutical clinical trials. Although developing targeted treatments can be more expensive, it eliminates the complexities and costs involved in the trial and error in traditional medicine development.

𝐖𝐡𝐚𝐭 𝐢𝐬 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐚𝐧𝐝 𝐢𝐬 𝐢𝐭 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞? 𝐆𝐞𝐭 𝐀 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 (220+ 𝐏𝐚𝐠𝐞𝐬 𝐏𝐃𝐅 𝐰𝐢𝐭𝐡 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐂𝐡𝐚𝐫𝐭𝐬, 𝐓𝐚𝐛𝐥𝐞𝐬, 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬) @ https://lnkd.in/dEKGsDXf As science evolves, healthcare is rapidly moving towards precision medicine, which offers a greater understanding of diseases using genetic insights and other medical advances in technology. Precision medicine, also known as personalised medicine, is a novel approach for disease treatment and prevention that considers the individual variability in genetics, environment, and lifestyle for each patient. This approach allows healthcare providers to make a more accurate diagnosis and create specialist treatment plans. Historically, the practice of drug development has largely been reactive. Patients must usually wait for the onset of symptoms before they are treated or cured. As we do not yet fully understand the genetic or environmental factors that cause some major diseases and leading causes of death such as Alzheimer’s and cancer, efforts to treat these diseases are often inaccurate and unsuccessful. This movement in medicine, away from a one-size-fits-all approach, is crucial as it provides not just the opportunity to reduce the adverse side effects but also has the potential to reduce the cost of treatments by eradicating ineffective treatment plans. Drugs and treatments created by pharmaceutical companies are often used to treat broad populations and consequently, they work for some patients but not others. It is estimated that any given prescription drug that makes it to market only works for half of those who take it. By considering each patient as an individual, precision medicine has the potential to overcome the limitations of traditional medicine by shifting the emphasis from reaction towards prevention. 𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐛𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐨𝐟 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞? By identifying the risk of a patient developing a disease they can be provided with an effective prevention plan, reducing unnecessary suffering for patients. This is also beneficial to society as it lessens the financial burden of illness and ineffective treatments on healthcare systems. If patients do contract a disease, then precision medicine has the potential to prevent unfavourable side effects. With medical precision, it is also possible to identify the most beneficial treatment plan before trying other methods, speeding up the recovery process and potentially extending life expectancy. Precision medicine also reduces the time, cost and failure rate of pharmaceutical clinical trials. Although developing targeted treatments can be more expensive, it eliminates the complexities and costs involved in the trial and error in traditional medicine development.

Order your 'Global Digital Therapeutics & Medical Devices for Migraine Market - Forecasts to 2029' FREE Sample Report via https://lnkd.in/dCjxriRe Wondering about the rapid growth of the Migraine Market in relation to Digital Therapeutics & Medical Devices by 2029? Let's dive into the key factors driving this expansion in the Healthcare industry! Unlock the Executive Summary of the report at only USD 249. Book a call now: https://lnkd.in/dFh7dy2X Firstly, advancements in technology have paved the way for innovative solutions targeting migraine management. From wearable devices that track physiological indicators to mobile applications offering personalized treatment plans, digital therapeutics and medical devices are revolutionizing how we approach migraine care. As someone who has personally dealt with migraines, I can attest to the importance of effective treatment options. The traditional approach often involves medication and lifestyle modifications, but the emergence of digital therapeutics provides additional avenues for managing symptoms and improving overall quality of life. Moreover, the rising prevalence of migraines worldwide is fueling the demand for more accessible and personalized treatment options. According to the Migraine Research Foundation, migraine affects approximately 1 billion people globally, making it the third most prevalent illness in the world. This growing patient population underscores the need for innovative solutions that cater to diverse needs and preferences. Additionally, increased awareness and destigmatization surrounding migraines are driving patients to seek out alternative treatment modalities, including digital therapeutics and medical devices. With more individuals actively seeking solutions to manage their migraines, there's a growing market opportunity for companies investing in this space. Furthermore, regulatory advancements and favorable reimbursement policies are facilitating the adoption of digital therapeutics and medical devices in migraine management. Regulatory bodies are increasingly recognizing the potential of these technologies to complement traditional treatments and improve patient outcomes. In conclusion, the rapid growth of the Migraine Market in relation to Digital Therapeutics & Medical Devices by 2029 is driven by a combination of technological innovation, increasing patient demand, regulatory support, and market dynamics. I'm curious to hear your thoughts on the future of migraine treatment and the role of digital therapeutics and medical devices! Drop a comment below and let's discuss. Theranica Bio-Electronics Ltd. CEFALY Technology WeatherX Aculief Allay Therapeutics Shakti Mats #GlobalDigitalTherapeuticsMedicalDevicesforMigraineMarket #GlobalMarketEstimates #GME #HealthcareInnovation #MigraineManagement #DigitalTherapeutics #MedicalDevices #FutureTrends

Recent Investments News on #CriticalLimbIschemiaTreatmentMarket The Critical Limb Ischemia (CLI) treatment market is experiencing significant investment activity as key players enhance their portfolios and technologies. Here’s a snapshot of the latest developments: Medtronic (Medtronic): Medtronic recently invested $200 million to advance its minimally invasive revascularization technologies, aimed at improving patient outcomes in CLI. Their new product line is expected to launch in Q2 2025. Boston Scientific (Boston Scientific): Boston Scientific has announced a strategic partnership with a leading AI company to develop next-gen imaging systems for CLI diagnosis, with an investment of $150 million. Abbott (Abbott): Abbott is expanding its CLI treatment portfolio with a $180 million investment in its endovascular technologies, including a new suite of stents and balloon catheters. COOK (Cook Medical): COOK Medical has secured $120 million to enhance its advanced peripheral interventions, focusing on improving CLI treatment efficiency. Cardiovascular Systems (Cardiovascular Systems, Inc.): Cardiovascular Systems is investing $100 million into clinical trials for its new drug-coated balloon technology aimed at better managing CLI. Terumo (Terumo Blood and Cell Technologies): Terumo has announced a $90 million investment to expand its CLI treatment solutions and support global clinical trials. B. Braun (B. Braun Group): B. Braun is investing $110 million into developing innovative devices and solutions for CLI, enhancing their endovascular treatment portfolio. Biotronik (BIOTRONIK): Biotronik's recent $85 million investment focuses on improving its CLI therapy devices, including a new generation of drug-eluting stents. MicroPort Medical (MicroPort): MicroPort Medical has allocated $95 million to develop advanced technologies for CLI treatment, focusing on enhancing procedural efficiency. Lepu Medical (Lepu Medical Technology (Beijing) Co., Ltd.): Lepu Medical is investing $70 million in expanding its CLI treatment product line and supporting R&D for new therapeutic solutions. Read Report @ https://lnkd.in/gu35nDxA #Healthcare #MedicalDevices #Investments #CriticalLimbIschemia #CLI #VascularHealth #InterventionalCardiology #Endovascular #MedicalInnovation #PatientCare #HealthTech #MedicalResearch #InvestmentNews #ClinicalTrials #HealthcareInvestment #Cardiovascular #MedTech #DeviceDevelopment #ClinicalResearch #HealthcareTechnology #GlobalHealth #FutureOfMedicine #CriticalLimbIschemia #CLI #VascularInterventions #MedicalDeviceInvestment #CardiovascularInnovation #EndovascularSolutions #HealthTechInvestments #MedicalResearchFunding #HealthcareAdvancements #ClinicalTrials #MedicalDevices #CardiovascularSystems #Medtronic #BostonScientific #Abbott #COOKMedical #Terumo #BBraun #Biotronik #MicroPortMedical #LepuMedical #MicroMedicalSolutions

𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐂𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐂𝐚𝐫𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 2024-2032: 𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲: https://lnkd.in/d-2YUsqd As healthcare advances, the Therapeutic Critical Care Market is rapidly evolving, driven by increased demand for critical care solutions across hospitals and specialized facilities. With the global critical care market valued at approximately $48 billion in 2023, it is projected to reach a remarkable $73 billion by 2032, exhibiting a CAGR of 4.8% over the forecast period. This growth is spurred by rising incidences of chronic diseases, a greater need for intensive care units (ICUs), and advancements in life-saving medical technology. Critical care therapies are essential in improving outcomes for patients facing life-threatening conditions, often involving the use of high-performance medical equipment, specialized medications, and continuous monitoring systems. Segment-wise growth calculations and forecasts for consumption value are presented for the period 2024-2032, aiding businesses in targeting specific and lucrative market niches for expansion in the Therapeutic Critical Care Market. 𝐓𝐨 𝐊𝐧𝐨𝐰 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐜𝐨𝐩𝐞 𝐚𝐧𝐝 𝐃𝐞𝐦𝐚𝐧𝐝 𝐨𝐟 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐂𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐂𝐚𝐫𝐞 𝐌𝐚𝐫𝐤𝐞𝐭. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲:https://lnkd.in/d-2YUsqd 𝗕𝘆 𝗧𝘆𝗽𝗲:Mechanical Ventilation, Intravenous Fluid Delivery, Dialysis Equipment, Hemodynamic Monitoring, Nutritional Support Devices, Pharmaceuticals 𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻:Intensive Care Units (ICUs), Emergency Rooms (ERs), Post-Surgical Care, Trauma Units, Neonatal ICUs (NICUs), Cardiac Care Units (CCUs) 𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻:North America, Europe, Asia-Pacific, South America, Middle East & Africa 𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀:GE HealthCare, Philips, Medtronic, Fresenius Medical Care, Baxter International Inc., B. Braun Group Siemens , Getinge, Stryker Sage, Smiths Medical, ICU Medical, Edwards Lifesciences, Nihon Kohden America, ZOLL Medical Corporation, Asahi Kasei, Mindray, Teleflex., FUJIFILM Holdings America Corporation, Fisher & Paykel Healthcare, Abbott, Johnson & Johnson, 3M&C Health Systems , Thermo Fisher Scientific, Boston Scientific, Roche Diagnostics UK & Ireland, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. , Terumo Medical Corporation, Vyaire Medical, Henry Schein, Masimo, Cardinal Health, Merck KGaA, Darmstadt, Germany, Canon Medical Systems Corporation , CareFusion, BD, Genentech, Sanofi, Novartis, Pfizer #therapeuticcriticalcare #criticalcaremarket #healthcare #intensivecare #medicaldevices #healthtechnology #ICUs #emergencycare #marketanalysis #marketresearch #cagr #globalhealth

𝐍𝐞𝐞𝐝𝐥𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 2024-2032: 𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭:https://lnkd.in/g2m5AM4s The Needles Market is projected to experience substantial growth, with an estimated market value of $X billion in 2023, driven by advances in healthcare technology, the increasing prevalence of chronic illnesses, and the expansion of healthcare services worldwide. By 2032, the market size is expected to reach approximately $X billion, growing at a CAGR of X% over the forecast period. This growth trajectory is fueled by the rising demand for medical procedures that utilize needles, such as injections, vaccinations, and blood collection, especially in developing regions. Our comprehensive market research report on the Needles Market provides both quantitative and qualitative insights, offering a deep dive into industry trends, manufacturer profiles, regional analysis, types, and applications. It includes an overview of top competitors, product offerings, and market share estimates for 2024, along with a detailed exploration of segmental growth. This report also offers segment-wise growth calculations and forecasts for consumption value, covering 2024 to 2032, enabling businesses to identify lucrative market niches within the Needles Market for expansion opportunities. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐭𝐨 𝐊𝐧𝐨𝐰 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐜𝐨𝐩𝐞 𝐚𝐧𝐝 𝐃𝐞𝐦𝐚𝐧𝐝 𝐨𝐟 𝐭𝐡𝐞 𝐍𝐞𝐞𝐝𝐥𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭:https://lnkd.in/g2m5AM4s 𝗕𝘆 𝗧𝘆𝗽𝗲: Hypodermic Needles, Insulin Needles, Suture Needles, Blood Collection Needles, Dental Needles, Fine Needles, Spinal Needles, Biopsy Needles 𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Hospitals, Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Home Healthcare 𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa 𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: BD, Terumo Medical Corporation, Smiths Medical, Nipro Medical Corporation, B. Braun Group Melsungen, Medtronic, Novo Nordisk, Allison Medical, Owen Mumford, Vitrex Medical A/S, BD Henke-Sass, Wolf, Retractable Technologies, Inc, Albert Davidson industries (ADI) , Unilene SAC, JMI Syringes & Medical Devices Ltd., Baxter International Inc., Cardinal Health, Jiangsu Jichun Medical Devices Co., Ltd, Merit Medical Systems, Inc., Invacare U.S., NARANG MEDICAL LIMITED, Hindustan Syringes & Medical Device Ltd., Shandong Weigao Group Medical Polymer Co.,Limited., Double Medical Technology Inc., Hamilton Lane Biomatrix Water, Covidien (Medtronic Minimally Invasive Therapies Group) #needlesmarket #healthcareindustry #medicaldevices #marketresearch #marketanalysis #healthcareinnovation #globalmarket #regionalinsights #hypodermicneedles #sutureneedles

🌐 𝐏𝐚𝐫𝐨𝐱𝐲𝐬𝐦𝐚𝐥 𝐒𝐮𝐩𝐫𝐚𝐯𝐞𝐧𝐭𝐫𝐢𝐜𝐮𝐥𝐚𝐫 𝐓𝐚𝐜𝐡𝐲𝐜𝐚𝐫𝐝𝐢𝐚 (𝐏𝐒𝐕𝐓) 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐂𝐚𝐫𝐝𝐢𝐨𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐂𝐚𝐫𝐞 🫀 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/gcEyDCKU The Paroxysmal Supraventricular Tachycardia (PSVT) Market is witnessing steady growth, spurred by increasing awareness of cardiovascular health and advancements in medical treatments. PSVT is characterized by episodes of rapid heart rate that start and stop abruptly. This condition, while not typically life-threatening, can lead to significant discomfort and anxiety for patients, driving demand for more effective therapies. 🔹 Key Market Drivers: Growing prevalence of cardiovascular diseases: As the global population ages, the incidence of heart-related conditions, including PSVT, is rising. Technological advancements in diagnosis and treatment: Improved diagnostic tools like electrocardiograms (ECGs) and portable monitoring devices are aiding in early detection, while innovative treatments, such as catheter ablation and advanced medications, are improving patient outcomes. Increased patient awareness: Greater awareness of heart health and the symptoms of arrhythmias is leading to earlier diagnosis and treatment. 🔬 Treatment Options: Medications: Antiarrhythmic drugs, beta-blockers, and calcium channel blockers are frequently prescribed to manage PSVT episodes. Catheter Ablation: A minimally invasive procedure to destroy the abnormal electrical pathways in the heart causing PSVT. It has become a popular and effective treatment option with high success rates. Vagal Maneuvers: Non-invasive techniques, such as the Valsalva maneuver, can sometimes stop PSVT episodes without medication. 📊 Market Insights: North America dominates the PSVT market due to its advanced healthcare infrastructure, high cardiovascular disease prevalence, and access to cutting-edge medical technology. Europe and Asia-Pacific are experiencing growth due to increasing healthcare spending, improving medical infrastructure, and growing awareness about cardiovascular conditions. 💡 Challenges: High cost of advanced treatments: Procedures like catheter ablation can be expensive, limiting access in regions with less developed healthcare systems. Side effects of medications: Antiarrhythmic drugs can have side effects, which may deter some patients from long-term use. #Company GlaxoSmithKline Sanofi Pfizer Novartis Teva Pharmaceuticals Medtronic Glenmark Pharmaceuticals Abbott Boston Scientific #Diagnosis EPS Echocardiogram Holter Monitor Others #Application Hospital Specialty Clinic Others #Cardiology #PSVT #HeartHealth #ArrhythmiaTreatment #MedicalInnovation #CardiacCare #HealthcareMarket

🔬 𝗪𝗲𝗮𝗿𝗮𝗯𝗹𝗲 & 𝗜𝗺𝗽𝗹𝗮𝗻𝘁𝗮𝗯𝗹𝗲 𝗔𝗿𝘁𝗶𝗳𝗶𝗰𝗶𝗮𝗹 𝗞𝗶𝗱𝗻𝗲𝘆𝘀: 𝗥𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗶𝗻𝗴 𝗞𝗶𝗱𝗻𝗲𝘆 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 🧑⚕️🚀 Kidney disease patients often rely on dialysis or transplants, but artificial kidneys are changing the landscape! 🌍 These cutting-edge devices, designed to mimic natural kidney functions, offer new hope for those with 𝐞𝐧𝐝-𝐬𝐭𝐚𝐠𝐞 𝐫𝐞𝐧𝐚𝐥 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 (𝐄𝐒𝐑𝐃). 1. 𝙒𝙚𝙖𝙧𝙖𝙗𝙡𝙚 𝘼𝙧𝙩𝙞𝙛𝙞𝙘𝙞𝙖𝙡 𝙆𝙞𝙙𝙣𝙚𝙮 💼 🔧 𝑷𝒖𝒓𝒑𝒐𝒔𝒆: Provides continuous blood filtration, freeing patients from clinic-based dialysis. 🦾 𝑫𝒆𝒔𝒊𝒈𝒏: Lightweight, portable, and designed for mobility. Patients can go about daily life while receiving treatment! ✅ 𝗔𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲𝘀: 🔹️Reduces complications (like electrolyte imbalances) with continuous treatment. 🔹️Offers more freedom compared to stationary dialysis. ⚠️ 𝗣𝗼𝘀𝘀𝗶𝗯𝗹𝗲 𝗦𝗶𝗱𝗲 𝗘𝗳𝗳𝗲𝗰𝘁𝘀: 🔹️Device malfunctions or blockages. 🔹️Infection risk at catheter access points. 🔹️Electrolyte imbalances (potassium, sodium, calcium). 🔹️Blood clots or dizziness due to fluid removal. 📊 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀: Early tests (7 patients for 24 hours). More trials are needed for long-term validation. 2. 𝙄𝙢𝙥𝙡𝙖𝙣𝙩𝙖𝙗𝙡𝙚 𝘽𝙞𝙤𝙖𝙧𝙩𝙞𝙛𝙞𝙘𝙞𝙖𝙡 𝙆𝙞𝙙𝙣𝙚𝙮 🧠 🔧 𝑷𝒖𝒓𝒑𝒐𝒔𝒆: Combines silicon filters and living kidney cells to replicate natural kidney functions. 🌟 𝑫𝒆𝒔𝒊𝒈𝒏: Nanotechnology for filtration + biological components for hormone production. ✅ 𝗔𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲𝘀: 🔹️Eliminates the need for immunosuppressive drugs. 🔹️A permanent, long-term solution without dialysis or transplants. ⚠️ 𝗣𝗼𝘀𝘀𝗶𝗯𝗹𝗲 𝗦𝗶𝗱𝗲 𝗘𝗳𝗳𝗲𝗰𝘁𝘀: 🔹️Potential immune response or infection. 🔹️Blood clotting or filter malfunction. 🔹️Surgical risks like bleeding or inflammation. 📊 𝗖𝘂𝗿𝗿𝗲𝗻𝘁 𝗦𝘁𝗮𝘁𝘂𝘀: Preclinical trials with promising results from animal models. Human trials are next, pending FDA approval. 3. 𝙒𝙝𝙮 𝙄𝙩 𝙈𝙖𝙩𝙩𝙚𝙧𝙨 💡 Artificial kidneys provide new solutions for kidney disease, offering patients more freedom, fewer complications, and better quality of life. 𝐔𝐂𝐒𝐅’𝐬 𝐊𝐢𝐝𝐧𝐞𝐲 𝐏𝐫𝐨𝐣𝐞𝐜𝐭, led by 𝐃𝐫. 𝐒𝐡𝐮𝐯𝐨 𝐑𝐨𝐲, is making great strides in this field. 🔗 Stay tuned for more advancements in this 𝐥𝐢𝐟𝐞-𝐜𝐡𝐚𝐧𝐠𝐢𝐧𝐠 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲! Follow: PRIOBRATA BISWAS MEng ✅️ #ArtificialKidney #WearableTechnology #Bioengineering #KidneyHealth #UCSF #InnovationInMedicine #RenalCare #FutureOfHealthcare #KidneyProject #BiomedicalEngineering #Biomedical #DialysisAlternative #LifeChangingTech #HealthcareTech

Could recent breakthroughs in insulin pumps, heart failure treatments, and female health imaging reshape patient care and drive industry growth? This week’s #MedTech News roundup highlights how these innovations are setting the stage for transformative changes in healthcare.   Medtronic reported a strong first-quarter performance, with revenue rising 2.8% to $7.915 billion and profits up 31.7%, driven by innovations in insulin pumps, PFA, and neuromodulation. The company raised its full-year guidance slightly and highlighted key growth areas, including its partnership with Abbott and advancements in cardiovascular and neuroscience technologies. Medtronic's CEO, Geoff Martha, emphasised the positive impact of these innovations on both patient outcomes and shareholder returns.   https://lnkd.in/gK8_Gn6t   Johnson & Johnson announced plans to acquire heart failure implant company V-Wave for up to $1.7 billion, including an upfront payment of $600 million and potential milestone payments. The acquisition, set to close by the end of 2024, will strengthen J&J MedTech’s position in the cardiovascular disease market, particularly with V-Wave's innovative Interatrial Shunt technology for heart failure treatment. This deal marks J&J's continued expansion in the heart disease devices sector, following significant investments in Shockwave Medical and Abiomed.   https://lnkd.in/gtbgrnjU   GE HealthCare has partnered with the University of California San Diego School of Medicine (UCSD) to explore advanced MRI techniques for female pelvic diseases and develop educational resources for clinicians. This collaboration aims to improve the diagnosis and management of conditions like endometriosis and ovarian cancer by increasing access to cutting-edge imaging technologies. Erin Angel, GE Healthcare’s global vice president of research and scientific affairs, expressed optimism that this project will empower clinicians with better tools and help bridge critical gaps in women’s healthcare worldwide.   https://lnkd.in/dgK4BH-B   Edwards Lifesciences has purchased the J-Valve transcatheter aortic valve replacement system from Genesis Medtech Group, along with intellectual property and commercial rights, while also making a $25 million equity investment in Genesis. This acquisition is part of Edwards' broader strategy, which recently included a $1.2 billion purchase of JenaValve Technology and Endotronix, along with other significant deals. Despite a slowdown in TAVR volumes, Edwards remains confident in its competitive position, continuing to invest heavily in expanding its heart valve technology portfolio.   https://lnkd.in/g5BmdXF2 #MedTechNews #MedTechIndustry #MedDeviceNews